Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Sotac Pharmaceuticals

SOTAC
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Sotac Pharmaceuticals Share price and Fundamental Analysis

View All Details
View All Details
Sotac Pharmaceuticals Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name of 'M/s Sotac Pharmaceuticals', pursuant to a Deed of Partnership dated October 28, 2015. Thereafter 'M/s. Sotac Pharmaceuticals' was converted from Partnership Firm to a Private Limited Company in the name of 'Sotac Pharmaceuticals Private Limited' dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat. Later on, Company converted into a Public Limited Company and the name of Company was changed to 'Sotac Pharmaceuticals Limited' dated November 22, 2022 issued by Registrar of Companies, Ahmedabad.
Company Incorporation2015
ChairmanSharadkumar Dashrathbhai Patel
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
151.99
PE Ratio
18.95
Industry P/E
33.01
PEG Ratio
0
ROE
15.07%
ROCE
14.13%
ROA
7.46%
Total Debt (Cr)
20.12
Debt to Equity
0.82
Dividend Yield
0%
EPS
7.26
Book Value & P/B
47.99 x 2.87
Face Value
10
Outstanding Shares(Cr)
1.11
Current Ratio
3.17
EV to Sales
2

Stock Returns

1 Week+5%
1 Month+10.97%
6 Months+33.54%
1 Year-6.59%
3 Years+13.91%
5 Years+13.91%
no_data

No Stocks

Smart Score

1.7
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 72.85%

FIIs : 15.12%

DIIs : 0.00%

Public : 12.03%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Increased by 6.23% to 15.12% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Sotac Pharmaceuticals Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Sotac Pharmaceuticals Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Sotac Pharmaceuticals Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name of 'M/s Sotac Pharmaceuticals', pursuant to a Deed of Partnership dated October 28, 2015. Thereafter 'M/s. Sotac Pharmaceuticals' was converted from Partnership Firm to a Private Limited Company in the name of 'Sotac Pharmaceuticals Private Limited' dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat. Later on, Company converted into a Public Limited Company and the name of Company was changed to 'Sotac Pharmaceuticals Limited' dated November 22, 2022 issued by Registrar of Companies, Ahmedabad.

The Company is a part of SOTAC Group, based at Gujarat and is engaged in manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis. The Company is pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, beta-lactam coated tablets, beta-lactam uncoated tablets, Non Beta-Lactam (general) capsules, beta-lactam capsules, oral liquid, dry syrup and external preparations such as nasal spray, relief spray and cream.

The Company's therapeutic portfolio include Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, AntiAllergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, AntiPyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams & Non-IP-Lactams, Anti-Fungal, Cephalosporin. Consequently, as a Group, it cater to a wide spectrum of companies for formulation development, clinical batch production, commercial scale productions.

The Company commenced manufacturing facility in year 2017, which had an installed capacity to manufacture 90 Crore tables / year, 14 Crore Capsules / year. Later, in 2022, the Company acquired 71% holding in SOTAC Healthcare Private Limited and 100% holding in SOTAC Research Private Limited, thus making them as wholly owned Subsidiary Companies in April, 2022. Thereafter, it started a new venture, SOTAC Lifescience Private Limited and held 51% of total paid-up capital in it.

The Company is planning to come out with a Initial Public offer consisting of upto 30,00,000 Equity Shares through Fresh issue.

Sotac Pharmaceuticals Share Price

Sotac Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Sotac Pharmaceuticals Market Cap

Market capitalization of Sotac Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Sotac Pharmaceuticals is valued compared to its competitors.

Sotac Pharmaceuticals PE Ratio

Sotac Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Sotac Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Sotac Pharmaceuticals PEG Ratio

The PEG ratio of Sotac Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Sotac Pharmaceuticals ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Sotac Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Sotac Pharmaceuticals ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Sotac Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Sotac Pharmaceuticals Total Debt

Total debt of Sotac Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Sotac Pharmaceuticals Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Sotac Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Sotac Pharmaceuticals CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Sotac Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Sotac Pharmaceuticals Technical Analysis

Technical analysis of Sotac Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Sotac Pharmaceuticals Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Sotac Pharmaceuticals shares often struggle to rise above due to selling pressure.

Sotac Pharmaceuticals Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Sotac Pharmaceuticals ’s financial health and profitability.

Sotac Pharmaceuticals Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Sotac Pharmaceuticals Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Sotac Pharmaceuticals Financials

The financials of Sotac Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Sotac Pharmaceuticals Profit and Loss Statements

The profit and loss statement of Sotac Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Sotac Pharmaceuticals .

Sotac Pharmaceuticals Balance Sheet

The balance sheet presents a snapshot of Sotac Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Sotac Pharmaceuticals Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.